Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous Activated T-Cells Transduced with a 3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase9 Safety Switch Administered to Patients with Relapsed or Refractory Neuroblastoma (GRAIN)

Next Previous
Trial Profile

Autologous Activated T-Cells Transduced with a 3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase9 Safety Switch Administered to Patients with Relapsed or Refractory Neuroblastoma (GRAIN)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 26 Dec 2015 Planned End Date changed from 1 Nov 2030 to 1 Oct 2030, according to ClinicalTrials.gov record.
  • 26 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
  • 30 Oct 2015 Planned End Date changed from 1 Aug 2030 to 1 Nov 2030 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top